SCHEMBL21393085

SCHEMBL21393085

CC(=O)N1OC1c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.47
MAOB P27338 4/20 0.41
ELANE P08246 1/20 0.40
TSHR P16473 2/20 0.39
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KIF11 P52732 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
EPHX1 P07099 1/20 0.36
NOTUM Q6P988 1/20 0.36
RIPK1 Q13546 1/20 0.36
HHAT Q5VTY9 1/20 0.36
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20142801 0.83 L3MBTL1 (0.41) POLBMAOBTSHRMEN1KMT2A
SCHEMBL22179555 0.80 L3MBTL1 (0.39) POLBTSHRMEN1KMT2AL3MBTL1
SCHEMBL21401879 0.79 BCHE (0.38) POLBL3MBTL1SMN1; SMN2KIF11RIPK1
SCHEMBL7190779 0.79 MEN1 (0.45) POLBELANETSHRMEN1KMT2A
SCHEMBL21392858 0.79 TSHR (0.46) TSHRMEN1HTTKMT2AL3MBTL1
SCHEMBL21392796 0.79 RIPK1 (0.45) POLBELANEL3MBTL1EPHX1RIPK1
SCHEMBL20160512 0.77 TSHR (0.51) POLBMAOBTSHRMEN1KMT2A
SCHEMBL21739343 0.75 P2RX4 (0.43) POLBMEN1HTTKMT2AL3MBTL1
SCHEMBL21739336 0.75 P2RX4 (0.45) POLBTSHRMEN1KMT2AL3MBTL1
SCHEMBL21739351 0.75 RORC (0.43) SMN1; SMN2EPHX1RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024064923-A9 COVALENT, CHEMOGENETIC ACTIVATORS FOR K2P POTASSIUM CHANNELS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-07-18 WO disclosed
US-11666661-B2 Methods and compounds for targeted autophagy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-06 US disclosed
WO-2021203016-A2 PROTEIN-PROTEIN INTERACTION STABILIZERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-10-07 WO disclosed
WO-2019183600-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-09-26 WO disclosed
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY FRONTIER MEDICINES CORPORATION 2019-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY ATG7, BECN1, SQSTM1 POLB 2880/4885MAOB 3325/4885ELANE 3891/4885
US-11666661-B2 Methods and compounds for targeted autophagy ATG7, BECN1, SQSTM1 POLB 2880/4885MAOB 3325/4885ELANE 3891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.